Factors Associated With Timely Measurement of Left Ventricular Ejection Fraction in New Onset Acute Heart Failure

s S113 significant increases in an established prognostic biomarker in HF, brain natriuretic peptide (BNP), for HFpEF (mean SEM, 188 34 pg/mL; p<0.001) and HFrEF (303 35 pg/mL; p<0.001) with respect to control (21 2 pg/mL). In the combined HF cohort, males had significantly higher ACE2 activity (48.2 3.0 vs. 35.3 3.6 pmol/hr/mL; p1⁄40.009), and while there was no significant difference in plasma ACE2 activity in response to obesity, hypertension or diabetes, BNP was significantly higher in non-obese compared to obese individuals (mean SEM, 222 35 pg/mL vs. 143 23 pg/mL; p1⁄40.011). ACE2 increased from mild to severe HF as per New York Heart Association (NYHA) class (I & II, 40.3 2.5 pmol/hr/mL vs. III & IV, 51.8 5.7 pmol/hr/mL; p1⁄40.037). CONCLUSION: Plasma ACE2 activity is increased in both types of HF and is similar within risk factor subgroups; this is in contrast to BNP, which varies in response to obesity.Males have higher plasma ACE2 activity than females, which reflects generally poorer outcomes for males. ACE2 is elevated in severe HF as compared to mild HF. These data suggest a potential utility of ACE2 as a prognostic biomarker in HF, particularly in patient subpopulations, such as obese persons, where traditional biomarkers, such as BNP, might have reduced efficacy. CIHR